Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms